{
    "data": [
        {
            "id": "3644176",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-04T11:32:37-05:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Accelerates In Q3: A Review Of The Quarter, The Company, And A Look Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164927",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3644176-regeneron-accelerates-in-q3-review-of-quarter-company-and-look-ahead"
            }
        },
        {
            "id": "3589166",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-21T11:06:49-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Politics Vs. Pills: A Biotech Stocks Buying Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "164124",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3589166-politics-vs-pills-biotech-stocks-buying-opportunity"
            }
        },
        {
            "id": "3565106",
            "type": "article",
            "attributes": {
                "publishOn": "2015-10-13T05:04:27-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "InsiderInsights.com Daily Round Up 10/8/15: REGN, MDGN, WHF, CAPL",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "27671",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3565106-insiderinsights-com-daily-round-up-10-8-15-regn-mdgn-whf-capl"
            }
        },
        {
            "id": "3527516",
            "type": "article",
            "attributes": {
                "publishOn": "2015-09-22T17:25:29-04:00",
                "isLockedPro": false,
                "commentCount": 137,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Reassessing Biotech Stocks After The Renewed Sell-Off: Focus On Regeneron",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "162694",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3527516-reassessing-biotech-stocks-after-renewed-sell-off-focus-on-regeneron"
            }
        },
        {
            "id": "3468626",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-26T13:17:44-04:00",
                "isLockedPro": false,
                "commentCount": 114,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Comments On The Market Correction; Focus On Biotechs: Large Caps",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "161322",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3468626-comments-on-market-correction-focus-on-biotechs-large-caps"
            }
        },
        {
            "id": "3401245",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-05T10:32:16-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Pharmaceuticals: 2 More Factors That Could Boost Stock Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "160088",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3401245-regeneron-pharmaceuticals-2-more-factors-that-could-boost-stock-price"
            }
        },
        {
            "id": "3395525",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-04T12:22:53-04:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Aims For $1000 As Its Growth Accelerates Yet Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "160026",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3395525-regeneron-aims-for-1000-as-its-growth-accelerates-yet-again"
            }
        },
        {
            "id": "3367745",
            "type": "article",
            "attributes": {
                "publishOn": "2015-07-30T06:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron's Mega-Blockbuster Potential With Praluent: CVS Health Sees It, So Why Don't More Analysts?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "57342",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "159628",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3367745-regenerons-mega-blockbuster-potential-with-praluent-cvs-health-sees-it-so-why-dont-more-analysts"
            }
        },
        {
            "id": "3304345",
            "type": "article",
            "attributes": {
                "publishOn": "2015-07-06T08:50:03-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Praluent Could Be Blockbuster For Regeneron",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "83226",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "158216",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3304345-why-praluent-could-be-blockbuster-for-regeneron"
            }
        },
        {
            "id": "3284245",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-25T14:46:30-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron's Growth Governed By 3 Key Prospects",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "89226",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "157734",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3284245-regenerons-growth-governed-by-3-key-prospects"
            }
        },
        {
            "id": "3203966",
            "type": "article",
            "attributes": {
                "publishOn": "2015-05-21T16:31:15-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Sanofi And Regeneron's Other Potential Blockbuster",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "47291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3203966-sanofi-and-regenerons-other-potential-blockbuster"
            }
        },
        {
            "id": "3167836",
            "type": "article",
            "attributes": {
                "publishOn": "2015-05-11T08:02:13-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Beats, Raises And Accelerates Its Late-Stage Product Development",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "155112",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3167836-regeneron-beats-raises-and-accelerates-its-late-stage-product-development"
            }
        },
        {
            "id": "3016126",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-20T06:56:30-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Pharmaceuticals' Likely Q1 Miss Won't Be So Bad",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "152460",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3016126-regeneron-pharmaceuticals-likely-q1-miss-wont-be-so-bad"
            }
        },
        {
            "id": "3009876",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-18T09:15:10-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Pharmaceuticals: Some Uncertainty Near Term, But Maintaining My Bullish Outlook",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3009876-regeneron-pharmaceuticals-some-uncertainty-near-term-but-maintaining-my-bullish-outlook"
            }
        },
        {
            "id": "2977116",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-06T14:35:49-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Jumps Ahead In $10 Billion Race For Next Generation Cardio Drugs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "57342",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "151652",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/2977116-regeneron-jumps-ahead-in-10-billion-race-for-next-generation-cardio-drugs"
            }
        },
        {
            "id": "2912026",
            "type": "article",
            "attributes": {
                "publishOn": "2015-02-13T13:43:56-05:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Regeneron's Risk-Reward Looks Good Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "150656",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/2912026-why-regenerons-risk-reward-looks-good-again"
            }
        },
        {
            "id": "2903776",
            "type": "article",
            "attributes": {
                "publishOn": "2015-02-10T15:03:16-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron: Mixed Earnings, But A Leg Up In The Cholesterol Race",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2903776-regeneron-mixed-earnings-but-a-leg-up-in-the-cholesterol-race"
            }
        },
        {
            "id": "2863856",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-30T12:12:40-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regeneron Shows Biotech Investors Have Left Their Wildcatting Days",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24276",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "149831",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2863856-regeneron-shows-biotech-investors-have-left-their-wildcatting-days"
            }
        },
        {
            "id": "2832376",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-20T09:44:50-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Week That Was: Healthcare Outlook Remains Excellent",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "149139",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2781",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2832376-the-week-that-was-healthcare-outlook-remains-excellent"
            }
        }
    ]
}